Clinical trial NCT02874079: Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
Official title: Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bullous Pemphigoid
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2016-08-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Autoimmune bullous dermatoses include pemphigus, bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucous membrane pemphigoid, lichen planus pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Autoimmune bullous dermatoses are rare and have an incidence of 20-60 new cases per 1 million person- year in Europe. The incidence of the individual entities is slight significantly different within Europe, but strongly also in comparison to other countries such as Kuwait, Singapore, USA and South America. The most common of these disorders is the bullous pemphigoid.

A considerable progress has been made in the last years to elucidate the pathogenic role of autoantibodies in these diseases. To this end, various in vitro and animal experiments have been used to understand some basic pathophysiological mechanisms in these diseases. Further studies are currently being carried out to explain a precise elucidation of the disease process and to be able to treat the patients targeted later.

At present, however, no data are available to explain why certain individuals develop the autoimmune disease and others do not. Epidemiological studies showed some triggers to the development of autoimmune dysregulation, e.g. drugs.

Furthermore, it has been shown that genetic factors play a role in the pathogenesis of the disease. A clear association with certain HLA regions have been shown in patients with pemphigus, e.g. about 95% of pemphigus patients from the group of Ashkenazi Jews have the HLA-DRB1\*0402 haplotype. Recently, the first non-HLA gene associated with pemphigus was described. For other conditions such as bullous pemphigoid, pemphigoid gestationis or linear IgA dermatosis the association with HLA antigens is less pronounced. Another indication of the importance of the genetic background in these diseases can be elucidated from the observation of autoantibodies at a low concentration in healthy relatives of pemphigus patients.

Detailed description: Study genetic and microbiologic predisposition of patients developing a bullous pemphigoid from peripheral blood and skin flora.

Eligibility criteria: Inclusion Criteria:

* patients with bullous pemphigoid in active phase
* patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
* patient consenting to participate to the study
* patient enrolled in the national healthcare insurance program
* patient older than 18 years

Exclusion Criteria:

- patients with pemphigoid gestationis

Primary outcomes:
measure: HLA haplotype
timeFrame: Day 1
Secondary outcomes:
measure: micro satellite markers
timeFrame: Day 1
measure: SNPs (single nucleotide polymorphisms)
timeFrame: Day 1
measure: Skin's Bacteria
timeFrame: Day 1
Other outcomes:
Locations:
city: Reims
country: France
facility: Chu de Reims
Study officials:
References: